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Abstract
Rationale: Emphysema and osteoporosis are epidemiologically associated diseases of cigarette smokers. The causal
mechanism(s) linking these illnesses is unknown. We hypothesized autoimmune responses may be involved in both
disorders.
Objectives: To discover an antigen-specific autoimmune response associated with both emphysema and osteoporosis
among smokers.
Methods: Replicate nonbiased discovery assays indicated that autoimmunity to glucose regulated protein 78 (GRP78), an
endoplasmic reticulum chaperone and cell surface signaling receptor, is present in many smokers. Subject assessments
included spirometry, chest CT scans, dual x-ray absorptiometry, and immunoblots for anti-GRP78 IgG. Anti-GRP78
autoantibodies were isolated from patient plasma by affinity chromatography, leukocyte functions assessed by flow
cytometry, and soluble metabolites and mediators measured by immunoassays.
Measurements and Main Results: Circulating anti-GRP78 IgG autoantibodies were detected in plasma specimens from 86
(32%) of the 265 smoking subjects. Anti-GRP78 autoantibodies were singularly prevalent among subjects with radiographic
emphysema (OR 3.1, 95%CI 1.7–5.7, p = 0.003). Anti-GRP78 autoantibodies were also associated with osteoporosis (OR 4.7,
95%CI 1.7–13.3, p = 0.002), and increased circulating bone metabolites (p = 0.006). Among emphysematous subjects, GRP78
protein was an autoantigen of CD4 T-cells, stimulating lymphocyte proliferation (p = 0.0002) and IFN-gamma production
(p = 0.03). Patient-derived anti-GRP78 autoantibodies had avidities for osteoclasts and macrophages, and increased
macrophage NFkB phosphorylation (p = 0.005) and productions of IL-8, CCL-2, and MMP9 (p = 0.005, 0.007, 0.03,
respectively).
Conclusions: Humoral and cellular GRP78 autoimmune responses in smokers have numerous biologically-relevant pro-
inflammatory and other deleterious actions, and are associated with emphysema and osteoporosis. These findings may
have relevance for the pathogenesis of smoking-associated diseases, and development of biomarker immunoassays and/or
novel treatments for these disorders.
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Introduction
Emphysema, defined as radiologic and/or histological evidence
of lung parenchymal destruction, accounts for enormous world-
wide morbidity and mortality [1]. Emphysema among tobacco
smokers often occurs in association with chronic obstructive
pulmonary disease (COPD), a complex syndrome typified by
airway narrowing and inflammation, and diagnosed by the
presence of expiratory airflow obstruction on spirometric testing
[1–4]. Nonetheless, emphysema and COPD are by no means
invariably concordant, and many patients severely afflicted by one
of these lung abnormalities may have little or no evidence of the
other [2–4]. In addition to directly attributable disability and
premature deaths, smoking-associated lung diseases are also linked
to many systemic abnormalities, including vasculopathies [5], lung
cancer [6], renal dysfunction [7], and osteoporosis [8]. The
abnormal and often pathological bone demineralization that
occurs in smokers is particularly notable for being highly related to
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the presence and severity of emphysema, and is independent of the
co-existence or magnitude of COPD per se [8].
While tobacco smoking is the single greatest risk factor for the
development of lung disease in industrialized societies, additional
mechanisms are also important, since only a fraction of heavy
smokers have severe clinical manifestations [1]. Moreover,
symptomatic, pathologic, and radiographic features are highly
variable among afflicted individuals, familial clustering of cases is
evident, and the disorders often progress despite smoking cessation
[1,4,9,10]. The pathophysiological processes that cause or
promote emphysema and its co-morbidities remain enigmatic,
although systemic immunological responses, including the actions
of activated monocyte-lineage phagocytes, have been implicated in
these disorders [11,12].
Adaptive immune responses against a variety of autoantigens
appear to be common among patients with lung disease
attributable to smoking [13–15]. Unspecified autoantibodies from
smokers have been shown to induce pulmonary epithelial cell
cytotoxicity in vitro. [13] Immune complex and complement
depositions are important mediators of autoantibody-induced
tissue injury, and these abnormalities are also prevalent in the
diseased lungs of smokers [13,14]. Nonetheless, most reports of
autoimmunity in patients with smoking-related lung disease to
date are correlative rather than mechanistic. To our knowledge,
moreover, no antigen-specific immune response has yet been
implicated in the systemic co-morbidities of these pulmonary
disorders [5–8].
Given the systemic nature of many immunological processes
[16–19], we hypothesized autoimmune responses that could
contribute to lung parenchyma destruction may also be involved
in pathogenesis of one or more extrapulmonary co-morbidities
that are associated with the emphysema. Accordingly, we
conducted investigations to identify antigen-specific autoimmune
responses relevant to both emphysema and osteoporosis in smoke-
exposed subjects.
Methods
Subjects
Clinical and immunological correlation studies were performed
in consecutive subjects with $10 pack-years of cigarette smoking,
ages 40–79 years old, who were recruited under auspices of the
Specialized Center for Clinically Oriented Research (SCCOR)
registry at the University of Pittsburgh Medical Center. Subjects
with unstable cardiovascular disease, malignancies, chronic oral
steroid use, or BMI .35 were excluded. Each subject completed
demographic and medical history questionnaires, and chest CT
scans [6–8,13]. Spirometry, lung volumes, and diffusion capacity
(DLCO) were measured using standardized methods and refer-
ence equations. Healthy, never-smoked control subjects were
recruited by solicitation of hospital personnel.
Ethics Statement
The protocol was approved by the University of Pittsburgh
Investigational Review Board. Each subject provided written
informed consent.
Emphysema Assessments
Chest CT examinations were performed with a General Electric
(GE) LightSpeed VCT (64-detector) scanner at a radiation
exposure of 100 mAs [6,8]. A single expert radiologist, blinded
to subject identities and other characteristics, interpreted the CT
images using a validated [6]. 6-point semi-quantitative visual
scoring system to define emphysema severity (0 = none, 1= trace/
minimal, 2 =mild, 3 =moderate, 4 = severe, 5 = very severe),
corresponding to 0%, ,10%, 10–25%, 26–50%, 51–75%, and
.75% visual emphysema [6–8]. Our group has previously shown
these visual emphysema scores are associated with clinically
important outcomes in smokers [6–8], and the validity and
comparability of these assessments with other radiographic
measures of emphysema has also been established [2,3].
Blood Specimens
Plasma was obtained by centrifugation of heparinized phlebot-
omy specimens. Peripheral blood mononuclear cells (PBMNC)
were isolated by density-gradient centrifugation [20]. Serum was
obtained as the supernatant of clotted (non-heparinized) blood.
Dual X-Ray Absorptiometry (DXA)
DXA measurements of bone mineral density (BMD) at the hip
and lumbar spine were added to subject assessments after the
initiation of enrollments in the SCCOR, and were available in the
last 200 smoking subjects who provided plasma for immunological
studies. Bone mineral density (BMD) was measured at the hip and
lumbar spine using a Hologic 4500A Discovery bone densitometer
and previously detailed methods [8]. BMD is reported as a T
score, the number of standard deviations from young, gender and
ethnic-specific reference means. T scores #22?5 defined osteo-
porosis [8].
Macrophages and Osteoclasts
CD14+ cells were isolated from PBMNC of normal, nonsmok-
ing humans using anti-CD14 immunomagnetic beads (Miltenyi
Biotec, Auburn, CA), and differentiated in the presence of M-CSF.
In brief, cells were cultured for 7–10 days in complete RPMI with
10% FCS that was also supplemented with 50 ng/ml M-CSF
(R&D Systems, Minneapolis, MN), and changed every 2–3 days.
Flow cytometry confirmed .98% of the cells harvested $day
seven expressed intracellular CD68+ and were CD32 and CD192.
Osteoclasts were derived from two healthy bone marrow donor
volunteers. Mononuclear cells within the bone marrow aspirates
were isolated by density gradient centrifugation and incubated in
a-MEM with 20% FCS overnight at 37uC. Non-adherent cells
were collected and cultured for 28 days in the same media
supplemented with 25 ng/ml M-CSF and 30 ng/ml RANKL
(R&D Systems), with frequent replenishment.
Autoantigen Discovery
The nonbiased discovery assays that resulted in identification of
autoreactivity to glucose regulated protein 78 (GRP78) among
smokers with lung disease parallel those reported previously [21].
In brief, we hypothesized a priori that autoantigens associated
with smoking-related emphysema could be identified by using
patient-derived IgG antibodies to immunoprecipitate these auto-
antigens from cell lysates. The biologic validity of the putative
autoimmunity could then be substantiated by demonstrating
correlations between the presence of humoral autoreactivity to
these self-proteins and disease prevalences. Additional evidence
could be provided by finding concurrent T-cell autoreactivity,
HLA bias, and discovering disease-relevant functional effects of
the autoantibody(ies) [15–21].
Pooled circulating IgG antibodies isolated from six emphyse-
matous subjects, known to have autoantibodies on previous study
[13], were used to immunoprecipitate autoantigens from cell
lysates. IgG from these subjects and another preparation from six
normal control specimens were isolated by protein G, and then
adhered to and covalently cross-linked to protein A columns (HP
GRP78 Autoreactivity in Smokers
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SpinTrap, GE Healthcare, Piscataway, New Jersey), per the
manufacturer’s protocol.
The cell lysates were preadsorbed with the normal IgG-protein
A columns, and then applied to the emphysema IgG-protein A
columns. After extensive washing, the putative IgG-bound
autoantigens were eluted by acidification, pH neutralized,
concentrated by centrifugal size-filtration (Millipore, Bellerica,
MA), and identified by two dimension 10.5% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Gels were
imaged by Typhoon TRIO (GE Healthcare) and analyzed by
Image QuantTL software (GE Healthcare). Individual proteins
were harvested by spot picking (Ettan Spot Picker, GE
Healthcare), trypsin digested, and sequenced by matrix-assisted
laser adsorption/ionization tandem time of flight mass spectrom-
etry (MALDI-TOF/TOF) (Applied Biosystems, Carlsbad, CA).
Unpublished findings of previous investigations [13] had
indicated the presence of an autoantibody with specificity for a
then cryptic ,75 kDa cell antigen tended to be associated with
disease manifestations among smokers, and hence discovery of
potential autoantigens of this ,size was a particular interest.
Glucose regulated protein 78 (GRP78), a member of the heat
shock protein 70 family, was identified in two sequential discovery
assays. In addition to having an appropriate size, GRP78 seemed
worthy of focus for additional study as a potential autoantigen in
smokers given its myriad cellular functions [22–24] and role as an
known autoantigen in other immunologic disorders [25,26].
Circulating Anti-GRP78 IgG
Immunoblots are a highly specific (‘‘Gold Standard’’) method
for detection of antibodies [21]. These assays were performed
using modifications of previously described methods. [21]
In brief, recombinant GRP78 (rGRP78) was purchased from
Prospec (Rehovot, Israel). rGRP78 was prepared as a bulk solution
and aliquots were frozen at 280uC until use. Volumes
corresponding to two hundred and fifty (250) ng rGRP78 were
concurrently added to multiple lanes of running gels (NuPage 4–
12% Bis–Tris, Invitrogen, Carlsbad, CA) and electrophoresed.
The proteins were transferred to nitrocellulose membranes and
blocked with 5% dry milk in TTBS (50 mM Tris HCl [pH 7.4],
150 mM NaCl, 0.1% Tween 20). Membrane strips were separated
by sectioning and each of these was individually incubated
overnight at 4o with a particular subject plasma specimen (@ 1:20
dilution). All of the laboratory investigators performing these
assays (RAK, JX, AB) concurrently incubated multiple subject
plasma specimens, each with one of the individual membrane
strips available from gels (plus positive and negative controls), as
well as molecular weight markers, and were completely oblivious
to subject identities or disease manifestations. Pilot study had
shown that 1:20 dilutions optimally distinguished emphysematous
from normal populations, whereas more dilute specimens were too
seldom positive in the disease subject specimens (and never
positive among normal specimens). The strips were washed in
TTBS, and then incubated for one hour with 1:8000 dilutions of
chicken anti-human IgG conjugated to horseradish peroxidase
(HRP) (Thermo Scientific, Rockfort, IL). After another washing,
HRP was detected by addition of Super Signal West Pico
Chemiluminescent Substrate (Thermo Scientific), instantaneous
exposure to radiographic film, and scored (positive or negative) by
unanimous consensus of three investigators who were blinded to
subject identities and clinical characteristics (Figure S1 in File S1).
The few equivocal specimens (n,5) were repeated until all blinded
judges were in agreement.
Lung Specimens
Tissue (,0.5–1 cm3) was dissected from emphysematous lungs
explanted during therapeutic transplantations and cadaveric
normal lungs that were not used as donor organs [20]. These
specimens were fixed in neutral buffer Zn-formalin, paraffin
embedded, and sectioned for immunohistochemistry (IHC) assays.
Bronchoalveolar lavage fluid (BALF) was obtained from lung
explants by wedging sterile 5 mm plastic tubing in segmental
bronchi, and successively infusing and aspirating 30 ml PBS
aliquots using a syringe. BALF was centrifuged (400 g), and the
supernatant was filtered (0.4 mm), concentrated using 3 kDa
centrifugation-size filters (Millipore, Billerica, MA), and quantified
by bicinchoninic acid (BCA) assay (Thermo Scientific). Alveolar
macrophages within BALF were isolated by plastic adherence.
Detection of GRP78 in Lung Specimens
Immunohistochemistry was used to assess in situ GRP78
expression in paraffin-embedded lung tissue sections [13,21]. In
brief, immunostaining was performed with a rabbit monoclonal
antibody directed against Grp78 (Cell Signaling Technology,
Danvers, MA) employing citrate antigen retrieval, as per the
manufacturer’s recommendation, biotinylated goat anti-rabbit
IgG Jackson Immunoresearch West Grove, PA), and AB Complex
HRP (Vector Laboratories, Burlingame, CA). Imaging methods
have been previously detailed [13,21].
GRP78 in BALF was detected by immunoblotting. Concen-
trated BALF (12 mcg protein) specimens were electrophoresed and
processed as described above. Membranes were incubated with
1:1000 dilutions of mouse anti-human GRP78 mAb (R&D
Systems) at 4uC, followed by 1:4000 dilutions of chicken anti-
mouse IgG-HRP (Santa Cruz Biotechnology, Santa Cruz, CA).
This immunoblotting method was validated using both commer-
cial rGRP78 and lysates of normal human CD14+-derived
macrophages (Figure S2 in File S1).
Patient-Derived Anti-GRP78 Autoantibodies
IgG from pooled plasma specimens of six emphysema patients
known to have anti-GRP78 autoantibodies (by prior immunoblot
assays) was isolated by adherence to protein G. The IgG was
applied to rGRP cross-linked to an AminoLink Plus Gel Spin
column (Thermo Scientific), following manufacturer protocols.
After extensive washing, anti-GRP78 was eluted by acidification,
pH neutralized, concentrated using 5 kDa centrifugation filters
and validated for IgG characteristics and specific avidity (Figure
S3 in File S1). Eleven (11) ml plasma yielded 120 mcg of anti-
GRP78 IgG. The endotoxin concentration within this autoanti-
body preparation was below the detection threshold of the limulus
amebocyte lysate assay (LAL Chromogenic Endotoxin Quantita-
tion Kit, Thermo Scientific), i.e., ,0.1 EU/2 mcg of autoanti-
body.
Indirect Immunofluorescence Assays (IFA)
Plate-bound normal alveolar macrophages from BALF (n= 3)
and bone marrow osteoclasts (n = 2) were pre-incubated with 0.1
bovine serum albumin and azide-free Fc receptor blocker (Innovex
Biosciences, Richmond, CA). After washing, the cells were
incubated for 30 minutes with 0.5 mcg/ml of patient-derived
anti-GRP78 IgG or the same concentration of pooled normal
human IgG. After another washing, cells were incubated with
FITC-conjugated anti-human IgG antibody (ImmunoConcepts,
Sacramento, CA) and assessed by fluorescence microscopy, as
detailed previously [13,21].
GRP78 Autoreactivity in Smokers
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Macrophage Stimulation Assays
Media was removed from concurrent, autologous macrophage
cultures, and the cells were incubated with 2 mcg/ml of either
anti-GRP78 or normal human IgG for 30 minutes at 37uC. Media
was then replaced, and both cells and supernatant were harvested
after 18 hours.
Macrophages were suspended, fixed and permiabilized, and
stained with anti-NFkB AlexFluor 647 (Cell Signaling Technolo-
gies, Danvers, MA), which has specificity for phosphorylated
(Ser536) NFkB p65 subunits. Mean fluorescence intensities of the
anti-GRP78-treated and normal IgG-treated macrophages were
compared in $10,000 live cells, and analyzed using a BD
FACSCalibur (BD Bioscience, San Jose, CA). Flow cytometry
gates were established using control fluorochrome positive and
negative macrophages (including isotype controls), as detailed
elsewhere [20,21].
Macrophage supernatants were analyzed for mediator produc-
tions using protein-suspended bead array platform multiplex kits
(Bio-Rad, Hercules, CA), following the manufacturer’s protocols
[21].
Bone Metabolites
Collagen type 1 C-telopeptide (CTX) was measured in sera by
sandwich immunoassays using CTX reagents in an Elecsys 2010
(Roche, Indianapolis, IN), according to manufacturer protocols.
Type 1 (N-terminal) Procollagen (P1NP) in plasma specimens was
measured using a radioimmunoassay kit (Orion Diagnostica,
Espoo, Finland).
Human Leukocyte Antigen (HLA) Class II DRB1*15
Allele prevalence was determined by leukocyte DNA PCR-SSP
[21]. Assessment of this particular allele was prompted by recent
findings it is over-represented among idiopathic pulmonary
fibrosis (IPF) patients with clinically-relevant autoimmunity [21].
T-cell Functional Studies
PBMNC collected from consecutive SCCOR subjects were
cultured for five days in complete media[13,20,21] in the presence
of no added protein (baseline controls), or test antigens (i.e.,
rGRP78 or elastin split products [ESP]). ESP was purchased from
Elastin Products Company (Owensville, MO). Both test antigens
were boiled for 20 minutes and cooled on ice immediately prior to
use, to obviate nonspecific mitogen effects, and added to cultures
at final concentrations of 1 mg/ml. Pilot studies had shown there
were no consistent relationships between test antigen concentra-
tions ranging from 0.3 mcg-to-30 mcg/ml and assay results.
Proliferation was determined by incorporation of bromodeoxy-
uridine (BrdU), added two days prior to cell harvest, with
measurements in gated CD4 T-cells established by flow cytometry,
as detailed previously [20,21]. Specific indices (SI) of proliferation
were calculated as %CD4 T-cells that incorporated BrdU in
cultures supplemented with the respective test antigen minus
incorporation in concurrent unstimulated (control) cultures [20].
Intracellular IFN-gamma production in the last cohort of these
culture specimens were also assessed by flow cytometry, using
methods fully detailed previously [20,21]. Specific indices (SI) of
IFN-gamma production were calculated as %CD4 T-cells that
produced this cytokine in cultures with added test antigen(s) minus
cytokine production in concurrent unstimulated (control) cultures.
Statistical Analysis
Ordered and continuous data were compared by Mann-
Whitney tests. Wilcoxon signed rank tests compared results of
two or more assays in the same specimen, with Bonferroni
corrections for multiple comparisons. Dichotomous outcomes
were analyzed by chi-square. Odds ratios (OR) and confidence
intervals (CI) were calculated with univariate logistic regression.
Multivariate logistic regression analysis was used to adjust for
confounding factors. Alpha levels ,0.05 were considered signif-
icant. All data was analyzed using SAS 9.2.
Results
Subjects
Characteristics of the smoke-exposure cohort are detailed in
Table 1. The majority (79%, n= 209) of the 265 smoking subjects
had one or more lung abnormalities (i.e., COPD and/or
emphysema). One-hundred thirty-three (133), or 80%, of the
167 subjects who had expiratory airflow obstruction on spirometry
(i.e., those who had COPD) also had emphysema. Conversely,
forty-two (42), or 24%, of the 175 emphysematous subjects had
normal spirometry. Another distinct cohort of healthy controls
who had never smoked (n = 27) were 5965 years old and 63%
were male.
Circulating Anti-GRP78 Antibodies
The prevalence of autoantibodies to GRP78 was greater in
smokers (32.2%) than in the healthy, never-smoked controls (7.4%)
(p = 0.007). The latter prevalence is similar to ‘‘false positive’’ rates
of other disease-associated autoantibodies in healthy populations
[13,16,20,21].
Females were over-represented among the smokers who had
anti-GRP78 autoantibodies (Table 1). Those who had anti-
GRP78 autoantibodies also had decreased diffusion capacities,
although their other pulmonary function tests, as well as
medication use, were comparable to the autoantibody negative
subjects.
HLA Class II DRB1*15 was under-represented among smokers
with anti-GRP78 autoantibodies (22.4%) compared to the subjects
who were autoantibody negative (34.7%) (OR 0.54, 95%CI= 0.3–
0.99, p = 0.04). DRB1*15 prevalence in a local normal population
was previously found to be 23% [21].
Clinical Associations of Anti-GRP78 Antibodies
There were no significant differences of anti-GRP78 autoanti-
body prevalences in the smokers with COPD (35.9%) compared to
those with normal spirometry (26.5%, p= 0.11), nor a significant
correlation of this autoreactivity with the severity of airflow
obstruction (Figure 1A).
However, the presence of anti-GRP78 autoantibodies was
significantly associated with the prevalence (Figure 1B) and
severity of emphysema (Figure 1C). Multivariate analyses showed
that adjustment for gender and severity of expiratory airflow
obstruction did not alter the relationship between anti-GRP78
positivity and emphysema (OR 3.1, 95%CI= 1.6–6.1, p = 0.001).
The presence of anti-GRP78 autoantibodies was also highly
associated with decreased bone mineral density and osteoporosis
(Figure 2A), and remained significant after multivariate adjust-
ment for gender, airflow obstruction severity, tobacco burden, and
steroid use (OR 4.2, 95%CI= 1.5–12.2, p = 0.008). Circulating
metabolites of bone turnover were also greatest in the subjects with
anti-GRP78 autoantibodies (Figures 2B,2C).
Given the associations of anti-GRP78 autoreactivity with
emphysema and abnormalities of bone mineralization, a post hoc
analysis was performed to compare autoantibody prevalence in
those subjects who have concurrent emphysema and low BMD
vs. the remaining smoking cohort. Anti-GRP78 autoantibody
GRP78 Autoreactivity in Smokers
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prevalence was significantly greater in the subjects who had both
emphysema and osteopenia (50.7% vs. 25%, OR 3.1,
95%CI= 1.8–5.4, p,0.0001), and even more so among those
with both emphysema and osteoporosis (80.0% vs. 29.6%, OR
9.5, 95%CI= 2.6–34.7, p,0.0001). A gender stratified analysis
showed this relationship is strongest in males (Figure 2D).
Intrapulmonary GRP78 Expression
GRP78 protein was and increased in emphysema specimens
and predominantly localized in alveolar epithelial cells and
macrophages (Figure 3A). GRP78 concentrations were also much
greater in BALF from diseased lungs compared to the normal
control preparations (Figure 3B).
Anti-GRP78 Binding
In order to explore the possibility that anti-GRP78 autoanti-
bodies have actions relevant to emphysema and osteoporosis, we
first examined macrophage and osteoclast binding of anti-GRP78
IgG isolated from patient plasma. IFA showed the anti-GRP78
autoantibodies have avidity for these cells (Figure 3C).
Cellular Effects of Anti-GRP78 Autoantibodies
To test for direct function-altering effects, patient-derived anti-
GRP78 autoantibodies were incubated overnight with macro-
phages. These treatments resulted in increased macrophage NFkB
activation (Figure 4A) and augmented productions of IL-8
(Figure 4B), CCL-2 (Figure 4C), and MMP9 (Figure 4D).
Table 1. Demographic and Clinical Characteristics of the Study Cohort.
Aggregate GRP78 Ab2 GRP78 Ab+ p value
Number 265 179 86
Age (years old)* 6760.4 6760.5 6760.7 NS
% male 58 63 47 0.01
Still smoking (%) 42 41 43 NS
Pack-years* 6362 6562 5963 NS
ICS (%) 22 20 28 NS
Past oral steroids (%) 7 7 7 NS
FEV1% predicted* 7761 7862 7463 NS
FEV1/FVC* 0.6360.01 0.6460.1 0.6060.2 NS
DLCO% predicted* 6862 7162 6462 0.02
Obstructed (%) 63 60 70 NS
Emphysema (%) 66 59 81 0.0003
Low Bone Density (%) 51 46 62 0.03
Osteoporosis (%) 9 4 18 0.002
All these subjects had$10 pack yr smoking histories. ICS = inhaled corticosteroid use; past oral steroids = oral steroid use within the preceding six months (none were
currently taking oral steroids); FEV1% predicted = forced expiratory volume in the first second of expiration as percentages of predicted values; FEV1/FVC = ratio of
FEV1 to forced vital capacity; DLCO% predicted = diffusing capacity for carbon monoxide as percentages of predicted values; Obstructed = subjects with spirometric
findings of expiratory airflow obstruction (i.e., COPD); Emphysema = subjects with emphysema on CT scan; p values are for nonparametric comparisons of smokers
who do not have anti-GRP78 IgG autoantibodies (GRP782) vs. subjects who have these autoantibodies (GRP78+); NS = not significant. * denotes data are depicted as
mean 6 standard errors.
doi:10.1371/journal.pone.0105066.t001
Figure 1. Anti-GRP78 autoantibodies, airflow obstruction, and emphysema. A.) Anti-GRP78 autoantibody prevalence was not significantly
associated with COPD severity (GOLD stages) [40]. Numbers within columns denote subject n. B.) Anti-GRP78 autoantibodies are significantly
associated with emphysema prevalence (%) in the smoking subjects. OR = odds ratio; CI = confidence interval. C.) Emphysema scores per CT were
also significantly greater among those subjects with anti-GRP78 autoantibodies.
doi:10.1371/journal.pone.0105066.g001
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CD4 T-cell Autoreactivity
Disease-associated autoantibody responses are also accompa-
nied by concurrent T-cell responses to the autoantigen(s)
[15,16,20,21]. Addition of heat-denatured rGRP78 protein to
PBMNC cultures from smokers induced proliferations of their
CD4 T-cells, unlike effects of denatured ESP (Figure 5A).
Moreover, the magnitude of the GRP78-triggered proliferative
responses was greatest among the CD4 T-cells from emphysema-
tous smokers (Figure 5B). CD4 T-cell IFN-gamma production was
also uniquely increased in rGRP78-supplemented cultures (Fig-
ure 5C) and, again, especially so in the preparations from subjects
with emphysema (Figure 5D). rGRP78 does not induce prolifer-
ation or IFN-gamma production in CD4 T-cells from normal
nonsmoking subjects (data not shown) nor IPF patients [21].
Discussion
Autoimmunity is a frequent complication of numerous, varied,
primary injury responses [15–18]. The microbiome within smoke-
damaged lungs is postulated to be highly immunogenic and,
hence, a likely predisposition for the development of autoimmunity
[13–15]. Neoantigens generated by reactive constituents within
tobacco smoke can also provoke autoimmune responses [14]. Most
‘‘secondary’’ autoimmune responses are benign and clinically
irrelevant. In some cases they are highly pathogenic and injurious,
however, as exampled by carditis associated with microbial
Figure 2. Anti-GRP78 autoantibody association with osteopo-
rosis, bone metabolism markers, and concurrent low bone
density and emphysema. A.) T scores (left panel) and osteoporosis
prevalence (at either/both hip or spine) (right panel) among the
smoking cohort. B.) Serum levels of bone turnover metabolite collagen
type 1 cross-linked C-telopeptide (CTX) were greatest among smokers
with anti-GRP78 autoantibodies. The lowest, second lowest, middle,
second highest, and highest lines represent 10th, 25th, median, 75th, and
90th percentiles, respectively. Means are denoted by solid squares. C.)
Serum levels of bone turnover metabolite type 1 (N-terminal)
procollagen (P1NP) were greatest among smokers with anti-GRP78
autoantibodies. D.) The relationship between GRP78 autoantibody
positivity and the concurrent co-existences of low BMD and emphy-
sema in smokers is significant in both genders, but greatest in males.
doi:10.1371/journal.pone.0105066.g002
Figure 3. GRP78 expression in lung, bronchoalveolar lavage
fluid, alveolar macrophages, and bone marrow derived
osteoclasts. A.) Compared to normal lung (Left panel), emphysema-
tous lungs (middle and right panels) demonstrated increased immu-
nostaining in macrophages (yellow arrows) and alveolar epithelial cells
(blue arrows). Magnification x100 left and middle panels, and
magnification x400 in the right panel, n = 3. B.) GRP78 was also greater
in bronchoalveolar lavage fluid (BALF) from emphysematous lungs
compared to normal preparations. Lanes 1 and 8 are rGRP78 standards.
Lanes 2–7 are BALF from individual emphysematous lung explants;
lanes 9–14 are BALF from normal lung explants. All specimen lanes
were loaded with equal amounts of BALF proteins. C.) Indirect
immunofluorescent assays showed anti-GRP78 IgG isolated from
patients bind to alveolar macrophages from normal lung explants
(panel a), and osteoclasts derived from bone marrow (panel b). Normal
human IgG control is illustrated in panel c.
doi:10.1371/journal.pone.0105066.g003
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infections, neurological syndromes linked to malignancies, and
myriad other tissue-specific autoimmune disorders [16–18,26].
The adaptive immune responses to GRP78 in smokers have
several features of classical autoimmunity [15–20]. The biological
plausibility of a particular autoimmune response is conditional on
the presence of the corresponding autoantigen in the target
organ(s), and GRP78 is highly expressed in lungs, especially in the
disease specimens (Figures 3A,3B). HLA haplotypes are major
(and often the strongest) known genetic determinants of autoim-
mune susceptibilities. Finding distinct HLA alleles are over- or
under-represented (conferring predilection or protection, respec-
tively) within a defined disease population is a hallmark of
autoimmune disorders [16,21]. DRB1*15 appears to ‘‘protect’’
smokers against the production of disease-associated anti-GRP78
autoantibodies. This result is the obverse of analogous studies in
IPF patients, in whom DRB1*15 is over-represented among those
with autoantibodies against heat shock protein 70 (HSP70), a stress
response protein with considerable sequence homology to GRP78
[21]. These disparate findings are thus indicative of biologically-
distinct, antigen- and disease-specific autoimmune responses,
rather than being a generalized epiphenomenon of ‘‘lung disease’’.
Most compellingly, the increased prevalence of anti-GRP78
autoantibodies in emphysematous smokers is a defining criteria of
‘‘abnormal’’ autoreactivity [15–20]. The pathogenicity of anti-
GRP78 IgG in smokers is at least implied by the stringent,
independent, and overlapping associations of this specific autoan-
tibody with concurrent emphysema, osteoporosis, and increased
bone turnover. Furthermore, other findings here showing that
patient-derived anti-GRP78 autoantibodies activate monocyte-
lineage phagocytes, and enhance their productions of injurious
mediators that are implicated in the genesis of emphysema and
osteoporosis are direct evidences of deleterious autoantibody
effects [11,12,27–29].
In particular, anti-GRP78 IgG treatments increased cellular
elaborations of IL-8 and CCL2 (aka MCP-1), which are potent
pro-inflammatory chemoattractants of neutrophils and mono-
cytes/macrophages, respectively. Both of these mediators also
stimulate osteoclastogenesis, and are increased among patients
with osteoporosis and emphysema [11,12]. Incubations with anti-
GRP78 also increased macrophage production of MMP9, a Type
IV collagenase produced by macrophages and osteoclasts that
promotes enzymatic breakdown of extracellular matrix. MMP9
has an imputed causal or contributing role in lung parenchyma
destruction, pulmonary metastases, and bone resorption [27–29].
Moreover, these varied effects occurred after only limited
(18 hour) macrophage exposures to subphysiological concentra-
tions (2 mg/ml) of the anti-GRP78 autoantibody. It seems possible
that even greater effects might result from incubations with
autoantibody concentrations found in vivo (,11 mg/ml), and for
longer periods. The cumulative effects of increased inflammation
and protease activity in target tissues over many months-to-years
may be especially deleterious, and emphysema and osteoporosis
Figure 4. Cellular effects of autoantibodies to GRP78 on macrophages. A.) Mean fluorescence intensity (MFI) for phosphorylated NFkB
among paired, concurrent autologous CD14+ derived macrophages was increased in all 10 normal specimens after incubation with patient-derived
autoantibodies to GRP78 (a-GRP78), relative to control cells treated with normal human IgG. Patient derived anti-GRP78 autoantibodies also
increased macrophage production of IL-8 (B.), CCL-2 (C.) and MMP9 (C.). Population means are denoted with a horizontal line.
doi:10.1371/journal.pone.0105066.g004
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are typically most prominent among middle-aged or elderly
smokers [1].
The in situ pathogenicity of GRP78 autoimmunity in smokers is
also strongly supported by finding this stress response protein is an
autoantigen of CD4 T-cells in these subjects, especially among
those with emphysema. T-cells are inert to anatomically accessible
self-constituents in healthy subjects, whereas overt reactivity of
these lymphocytes to a protein that is abundant in diseased organs
(Figures 3A,3B) is a ‘‘Gold Standard’’ of autoimmune disease
[16,19]. Antigen- (or autoantigen-) stimulated CD4 T-cells have
protean and typically very injurious actions, including elaboration
of numerous mediators that recruit and activate diverse leukocyte
and somatic effector cells [21]. A finding of T-cell autoreactivity is
very unlikely to be a benign epiphenomenon [16,19]. Increased
production of IFN-gamma in particular (Figures 5C,5D) is
believed to be an important factor in the pathogenesis of
smoking-associated lung disease [11]. Furthermore, the GRP78
reactivity of CD4 T-cells in emphysematous subjects cannot be
simply attributable to global, nonspecific hyperactivity, since
elastin split products (ESP) were inert (Figures 5A and 5C).
Although ESP was previously reported to be an autoantigen of
emphysema [30], we have been unable to replicate those findings,
and similarly negative studies have been reported by other
investigators [31–33].
GRP78 is also a frequent antigen of other autoimmune
syndromes [25,26]. GRP78 expression and extracellular export
are up-regulated by varied stresses, including viral infections and
smoke inhalation [22–24]. Ongoing immunologic responses that
were initially directed at other antigenic peptides may generalize
to co-associated chaperone proteins, such as GRP78, by a
bystander mechanism and/or by epitope spread [25]. Subsequent
injury (or infection) could cause further up-regulation of the newly
antigenic GRP78, potentially creating a positive feedback loop
that promotes immune responses and disease progression.
The specific mechanism(s) by which anti-GRP78 autoantibodies
affect phagocytes is yet unknown, and is a focus of ongoing
investigations in our laboratories. In addition to intracellular
actions as an endoplasmic reticulum protein transporter and
scavenger, and importance in the unfolded protein response, cell
surface and extracellular GRP78 mediate anti-inflammatory and
pro-resolutory effects [22–24]. Anti-GRP78 might counter these
actions by decreasing the concentrations or bioavailability of
immunomodulatory extracellular GRP78, and/or by activating
signal transduction pathways after cross-linking cell surface
GRP78. Anti-GRP78 autoreactivity is notably prevalent among
subjects with rheumatoid arthritis, another smoking-associated
disease, and the autoantibodies from these patients also enhance
macrophage pro-inflammatory functions, again, by mechanisms
still unknown [26].
The findings of GRP78 autoreactivity here lend support to an
evolving paradigm of autoimmune pathogenesis in smoking-
associated lung diseases [13–15]. The present studies show anti-
GRP78 responses in smokers are manifest by activation of
autoantigen-specific T-cells, a process that leads to numerous
deleterious consequences [19], and anti-GRP78 IgG autoantibod-
ies directly exert pro-inflammatory effects. Even if these patho-
genic actions are completely discounted, the multiple strong
clinical-immunological associations here indicate assays for specific
autoimmune responses may be useful to identify smokers who are
most at-risk for these interrelated disorders. Nonetheless, these
findings need additional corroboration and refinement before the
adoption of autoimmune assays into the clinical management of
smoking patients.
In addition, many immune diseases, and antibody-mediated
lung disorders in particular, are refractory to treatment with
nonspecific immunosuppressive regimens (e.g., glucocorticoids).
Conversely, however, specific therapies that directly target
pathological autoimmune processes, including autoantibody
removal or interruption of autoantibody production per se, more
often have clinical efficacy [34–39]. The most important ultimate
result of the present study and related reports may be to draw
attention to the potential for novel treatments, mechanistically-
focused at critical stages of autoimmune cascades, to prevent or
Figure 5. CD4 T-cell autoreactivity to GRP78. A.) Addition of
GRP78 to PBMNC cultures increased CD4 T-cell proliferation (BrdU
uptake) relative to media controls (no added protein) (n = 47), unlike
addition of elastin split products (ESP). Pc denotes alpha level corrected
for multiple comparisons. B.) GRP78-induced CD4 T-cell proliferation
was greatest among cultures from smokers with emphysema (n = 34).
Specific indices (SI) of proliferation were calculated as %CD4 T-cells
incorporating BrdU in GRP78-supplemented cultures minus incorpora-
tion in concurrent media controls. C.) GRP78 also increased percentages
of CD4 T-cells that produced IFN-gamma again, unlike effects of ESP. D.)
IFN-gamma production was also greatest in the CD4 T-cells from the
emphysematous smokers. Specific indices (SI) were calculated as %CD4
T-cells producing IFN-gamma production in GRP78-supplemented
cultures minus that of concurrent controls.
doi:10.1371/journal.pone.0105066.g005
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slow progression of the morbid and refractory syndromes
associated with smoking [15,34–39].
Supporting Information
File S1 Contains Figure S1, Immunoblot Detection of Anti-
GRP78 Autoantibodies. Detection of circulating anti-GRP78 IgG.
Immunoblots were used to detect circulating anti-GRP78
autoantibodies in plasma specimens See manuscript text for
methodological details. Left panel: 75 kDa molecular weight
marker (MW) and adjacent plasma specimen negative for anti-
GRP78 (Lane A). Right panel: 75 kDa molecular weight marker
(MW) and subject plasma specimen positive for anti-GRP78 IgG
(Lane B). Note: GRP78 migrates on 12% Bis–Tris gels as though it
were slightly smaller than its expected 78 kDa size. Figure S2,
Detection of GRP78 Protein in Lung Specimens. Control
immunoblots. Lane A.) rGRP detected with mouse anti-human
GRP78 monoclonal antibody (R and D Systems) at 1:500 dilution.
The secondary antibody was chicken anti-mouse human IgG at
1:4000 dilution. Lane B.) GRP78 in a human CD14+-derived
macrophage lysate (29 mg total protein) was also detected using
this anti-human GRP78 monoclonal antibody. MW.) 75 kDa
molecular weight marker. Figure S3, Patient-Derived Anti-GRP78
Autoantibody Characterizations. Validations of patient-derived
anti-GRP78 autoantibodies. Left panel: Evaluations of the patient-
derived anti-GRP78 on SDS gels showed protein bands typical for
IgG, i.e., 25 kDa light chains and 50 kDa heavy chains. Right
panel: The avidity of the isolated, patient-derived autoantibody for
GRP78 was confirmed by rGRP78 immunoblot. Lane A.) 75 kDa
molecular weight marker; Lane B.) rGRP78. The patient-derived
anti-GRP78 IgG was used here at a concentration of 1 mg/ml.
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